statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Alterity Therapeutics receives A$3.9M R&D Tax Incentive refund

MELBOURNE, AustraliaandSAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ( Alterity or the Company ), a biotechnology company...

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

Alterity Therapeutics Limited (NASDAQ:ATHE  Get Free Report) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 37,800...

Short Interest in Alterity Therapeutics Limited (NASDAQ:ATHE) Grows By 25.6%

Alterity Therapeutics Ltd (ADR) trading halted, news pending

Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease to be Presented at International Conference Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2...

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

- ATH434-201 Trial on Track to Complete in November 2024 - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Alterity...

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ( Alterity or the Company ), a biotechnology company dedicated to...

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Preliminary Data from ATH434-202 Study Expected in 1H 2024 ATH434-201 Study to Complete in November 2024 MELBOURNE, Australiaand SAN FRANCISCO, Jan. 22, 2024 (GLOBE NEWSWIRE...

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Alterity Therapeutics Limited (NASDAQ:ATHE  Get Free Report) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest...

Short Interest in Alterity Therapeutics Limited (NASDAQ:ATHE) Grows By 22.8%

Alterity Therapeutics (NASDAQ:ATHE  Get Free Report) and Atea Pharmaceuticals (NASDAQ:AVIR  Get Free Report) are both small-cap medical companies, but which is the superior investment...

Alterity Therapeutics (NASDAQ:ATHE) versus Atea Pharmaceuticals (NASDAQ:AVIR) Head to Head Comparison

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Volume	87,840.00
52-Wk High	$5.41
52-Wk Low	$1.55

ATHE Alterity Therapeutics Ltd - ADR

About

Feed

News

Sentiment

Fundamentals